Literature DB >> 18307533

Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci.

Katsuya Tsuchihara1, Tsutomu Ogura, Rumi Fujioka, Satoshi Fujii, Wataru Kuga, Marie Saito, Takahiro Ochiya, Atsushi Ochiai, Hiroyasu Esumi.   

Abstract

SNF-1/5'-AMP-activated kinase (AMPK)-related kinase (SNARK) is a member of the AMPK-related kinases. Snark(+/-) mice exhibited mature-onset obesity and related metabolic disorders. Obesity is regarded as a risk factor for colorectal cancer. To investigate whether Snark deficiency is involved in tumorigenesis in the large intestine, obese Snark(+/-) mice were treated with a chemical carcinogen, azoxymethane (AOM). The incidences of both adenomas and aberrant crypt foci (ACF) were significantly higher in Snark(+/-) mice than in their wild-type counterparts 28 weeks after the completion of AOM treatment (10 mg/kg/week for 8 weeks). Furthermore, ACF formation was enhanced in Snark(+/-) mice treated with AOM for 2 weeks, suggesting that Snark deficiency contributed to the early phase of tumorigenesis. The total number of ACF was correlated with bodyweight in Snark(+/-) and Snark(+/+) mice, suggesting that obesity was a risk factor for colorectal tumorigenesis in this model. However, the correlation coefficient was higher in Snark(+/-) mice. Moreover, AOM-induced ACF formation was also enhanced in preobese Snark(+/-) mice. Together, these findings suggest that AOM-induced tumorigenesis in Snark(+/-) mice was enhanced via obesity-dependent and -independent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18307533     DOI: 10.1111/j.1349-7006.2008.00734.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  12 in total

Review 1.  The LKB1 complex-AMPK pathway: the tree that hides the forest.

Authors:  Michaël Sebbagh; Sylviane Olschwang; Marie-Josée Santoni; Jean-Paul Borg
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

2.  The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.

Authors:  Kaku Goto; Wenyu Lin; Leiliang Zhang; Nikolaus Jilg; Run-Xuan Shao; Esperance A K Schaefer; Hong Zhao; Dahlene N Fusco; Lee F Peng; Naoya Kato; Raymond T Chung
Journal:  J Hepatol       Date:  2013-07-02       Impact factor: 25.083

3.  The AMPK-related kinase SNARK regulates muscle mass and myocyte survival.

Authors:  Sarah J Lessard; Donato A Rivas; Kawai So; Ho-Jin Koh; André Lima Queiroz; Michael F Hirshman; Roger A Fielding; Laurie J Goodyear
Journal:  J Clin Invest       Date:  2016-02       Impact factor: 14.808

Review 4.  Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance.

Authors:  Eijiro Yamada; Ting-Wen A Lee; Jeffrey E Pessin; Claire C Bastie
Journal:  Future Med Chem       Date:  2010-12       Impact factor: 3.808

5.  AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma.

Authors:  Takeshi Namiki; Atsushi Tanemura; Julio C Valencia; Sergio G Coelho; Thierry Passeron; Masakazu Kawaguchi; Wilfred D Vieira; Masashi Ishikawa; Wataru Nishijima; Toshiyuki Izumo; Yasuhiko Kaneko; Ichiro Katayama; Yuji Yamaguchi; Lanlan Yin; Eric C Polley; Hongfang Liu; Yutaka Kawakami; Yoshinobu Eishi; Eishi Takahashi; Hiroo Yokozeki; Vincent J Hearing
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-01       Impact factor: 11.205

6.  Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle.

Authors:  Ho-Jin Koh; Taro Toyoda; Nobuharu Fujii; Michelle M Jung; Amee Rathod; R Jan-Willem Middelbeek; Sarah J Lessard; Jonas T Treebak; Katsuya Tsuchihara; Hiroyasu Esumi; Erik A Richter; Jørgen F P Wojtaszewski; Michael F Hirshman; Laurie J Goodyear
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

Review 7.  AMPK and SIRT1: a long-standing partnership?

Authors:  Neil B Ruderman; X Julia Xu; Lauren Nelson; José M Cacicedo; Asish K Saha; Fan Lan; Yasuo Ido
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-01-26       Impact factor: 4.310

Review 8.  NUAK2: an emerging acral melanoma oncogene.

Authors:  Takeshi Namiki; Sergio G Coelho; Vincent J Hearing
Journal:  Oncotarget       Date:  2011-09

9.  Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes.

Authors:  A Rune; M E Osler; T Fritz; J R Zierath
Journal:  Diabetologia       Date:  2009-08-04       Impact factor: 10.122

10.  Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes.

Authors:  Arturo Bravo-Nuevo; Alice Marcy; Minzhou Huang; Frank Kappler; Jennifer Mulgrew; Lisa Laury-Kleintop; Melvin Reichman; Annette Tobia; George C Prendergast
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.